Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
Clinical trial NCT06253520 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06253520
- Sponsor
- National Cancer Institute (NCI)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-05-16
- Primary completion
- 2029-02-20
- Enrollment
- 210
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.